Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if durvalumab and trametinib can help to
control microsatellite stable (MSS) colorectal cancer. The safety of these drugs will also be
studied.
This is an investigational study. Durvalumab is FDA approved and commercially available for
the treatment of previously treated advanced bladder cancer. Trametinib is FDA approved in
combination with another drug called dabrafenib for the treatment of unresectable or
metastatic melanoma with BRAF V600E or BRAF V600K.
It is investigational to use durvalumab and trametinib to treat MSS colorectal cancer.
Up to 56 participants will be enrolled in this study. All will take part at MD Anderson.